**Name of Journal:** *World Journal of Orthopedics*

**Manuscript NO:** 66851

**Manuscript Type:** REVIEW

**Antibiotic-free antimicrobial poly (methyl methacrylate) bone cements: A state-of-the-art review**

Lewis G. Antimicrobial PMMA bone cement

Gladius Lewis

**G****ladius Lewis,** Department of Mechanical Engineering, University of Memphis, Memphis, TN 38152, United States

**Author contributions:** Lewis G controlled literature research and wrote the manuscript.

**Corresponding author: Gladius Lewis, PhD, Full Professor,** Department of Mechanical Engineering, University of Memphis, 312 Engineering Science Building, 3815 Central Avenue, Memphis, TN 38152, United States. glewis@memphis.edu

**Received:** April 7, 2021

**Revised:** November 30, 2021

**Accepted:** **March 4, 2022**

**Published online:**

**Abstract**

Prosthetic joint infection (PJI) is the most serious complication following total joint arthroplasty, this being because it is associated with, among other things, high morbidity and low quality of life, is difficult to prevent, and is very challenging to treat/manage. The many shortcomings of antibiotic-loaded poly (methyl methacrylate) (PMMA) bone cement (ALBC) as an agent for preventing and treating/managing PJI are well-known. One is that microorganisms responsible for most PJI cases, such as methicillin-resistant *S. aureus*, have developed or are developing resistance to gentamicin sulfate, which is the antibiotic in the vast majority of approved ALBC brands. This has led to many research efforts to develop cements that do not contain gentamicin (or, for that matter, any antibiotic) but demonstrate excellent antimicrobial efficacy. There is a sizeable body of literature on these so-called “antibiotic-free antimicrobial” PMMA bone cements (AFAMBCs). The present work is a comprehensive and critical review of this body. In addition to summaries of key trends in results of characterization studies of AFAMBCs, the attractive features and shortcomings of the literature are highlighted. Shortcomings provide motivation for future work, with some ideas being formulation of a new generation of AFAMBCs by, example, adding a nanostructured material and/or an extract from a natural product to the powder and/or liquid of the basis cement, respectively.

**Key Words:** Periprosthetic joint infection; Poly (methyl methacrylate) bone cement; Antibiotic-loaded poly (methyl methacrylate) bone cement bone cement; Antibiotic-free antimicrobial poly (methyl methacrylate) bone cement bone cement

Lewis G. Antibiotic-free antimicrobial poly(methyl methacrylate) bone cements: A state-of-the-art review. *World J Orthop* 2022; In press

**Core Tip:** Although antibiotic-loaded poly (methyl methacrylate) (PMMA) bone cements are widely used both as prophylactic agent and in the treatment/management of prosthetic joint infection, there is dissatisfaction about the material. A new generation of antibiotic-free antimicrobial PMMA bone cements (AFAMBCs) is emerging. The present review is a critical appraisal of the literature on AFAMBCs, highlighting its strengths, shortcomings, and possible areas for future studies. The conclusion is that state-of-the-art on AFAMBC formulations is such that it is premature to comment on the potential of any of the formulations for clinical application.

**INTRODUCTION**

Regardless of the patient group, periprosthetic joint infection (PJI) is a relatively rare occurrence; for example, 2 years after total hip arthroplasty (THA) and total knee arthroplasty (TKA), the cumulative incidence rate is on the order of between 0.5% and 0.8% and about 1.0% of cases, respectively[1,2]. Nonetheless, PJI is recognized as being the most challenging of complications of total joint arthroplasties (TJAs) (to the point of intractability) because of the associated risk for revision of the implant, increase in mortality, increase in morbidity, decrease in quality of life of the patient, and increased direct and indirect costs[3,4]. As such, PJI has been the subject of myriad studies, the bulk of which has been devoted to four aspects, these being identification and stratification of patient- and surgery-based risk factors, diagnosis, prevention, and treatment/management[4]. Among risk factors, the significant roles of morbid obesity (body mass index greater than 40 kg/m2), young age (< 50 years) of the patient, preoperative use of opioids by the patient, and prolonged surgery time (> 2 h) are recognized even though the supporting clinical evidence ranges from limited to moderate[5-8]. With respect to diagnosis, an assortment of methods is in current clinical use, such as 18F-labeled fluorodeoxyglucose-positron emission tomography (FDG-PET)[9], and measurement of synovial fluid biomarkers, notably, alpha-defensin[10], or under investigation, among which are measurement of temporal change in D-dimer level in conjunction with serum erythrocyte sedimentation rate and C-reactive protein level[11], use of monocyte/lymphocyte ratio, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio (PLR), and platelet/mean platelet volume ratio (PVR), in conjunction with other hematologic and aspirate markers[12], and landmark-guided hip aspiration[13]. To date, a gold standard has not emerged. The most widely used prevention method is anchoring the implant in a bed of antibiotic-loaded poly(methyl methacrylate) bone cement (ALBC)[4]. As for treatment/management, the two common approaches are: (1) Surgical debridement (debridement followed by intravenous or highly bioavailable oral delivery of antimicrobial medication specific to the microorganism found in the case (medical therapy) and retention of the implant (DAIR)[14,15]); and (2) Resection arthroplasty using two-stage exchange[16,17] (although, in recent years, in some countries, enthusiasm is being shown for one-stage exchange[18,19] followed by medical therapy[4,16]). In either option, it is common to fix the exchanged implant to the contiguous bone in an ALBC bed[16].

While an ALBC has a number of attractive features, chief among which are ease of preparation in the operating room and low intrinsic toxicity, it has its share of shortcomings and concerns. One shortcoming is its lack of bioactivity[20,21]. Another is the fact that the bacterial species that are responsible for PJI, most commonly, *S. aureus* and *S. epidermidis*[22], are becoming resistant to gentamicin sulfate, which is the antibiotic in the vast majority of ALBC brands approved by national regulatory bodies, such as the US Food and Drug Administration (the method of mixing of the antibiotic with the cement powder is proprietary) and physician-directed ALBC formulations (mixing of antibiotic and cement powder is carried out in the operating room)[4,23]. A third shortcoming is that the release profile of the antibiotic is sub-optimal, being characterized by 1) an initial short high release rate (zone lasts, typically, < 2 d), followed by a significant reduction in release rate, culminating in exhaustion of release after, typically, 20-30 d and 2) cumulative release of only, typically, between about 0.3% and about 13% of the loaded antibiotic[24,25]. Additionally, there is a lack of consensus that even with risk-stratified usage in primary TJA, the current generation of ALBCs is efficacious and cost-effective[26-36]. As for concerns about ALBC, there are long-standing ones, such as potential deleterious effect on mechanical properties of basis cement[37], and ones that have only recently been raised, such as an increase in immunological factors (specifically, soluble interleukin-6 and C-reactive protein) in patients in which there is a gentamicin-loaded cement implant, suggesting that unknown immunomodulatory pathways may be altered by an ALBC[38].

The aforementioned observations highlight the need for novel methods for reducing the risk for PJI whether ALBC is used as a prophylactic agent in primary THAs and TKAs (as is common practice in a number of countries, such as Norway, and limited use in others, such as United States) or during the second stage of a two-stage exchange arthroplasty (as is common practice in the United States[39]). This need has served as the driver for the large amount of research attention that has been given to this field. These efforts may be grouped into four approaches: application of an antimicrobial coating to part(s) of implant component(s), such as the proximal zone of the femoral stem of a THA[4,40-45]; use of ALBCs in which a relatively new antibiotic/antibacterial compound (for example, daptomycin[46] or a second-generation lipophosphonoxin[47]) is added to the cement powder; modification of the surface of the implant (for example, incorporation of an antibiotic-releasing polymer into the surface of a joint implant[48] and use of a nanofabrication method to create biomimetically-inspired nanostructures on an implant surface[49]); and proposed use of antibiotic-free antimicrobial PMMA bone cements (AFAMBCs)[50-68]. The focus of the present review is AFAMBCs, which have been the subject of many studies on their formulation and characterization[50-68]. However, to date, only one review of this body of literature has been published[69] but it has two shortcomings. First, only about half of that review was devoted to AFAMBCs, with the balance being on aspects such as PMMA bone cement and orthopaedic infections in general and details of the classification, diagnosis, and treatment of PJI. Second, some of the literature studies reviewed were not appropriate to bone cement use in TJAs; for example, the subject of the studies was cement for beads, blocks, and spacers for the treatment of severely contaminated open tibial fractures[70], bone reconstruction[71,72],cement used for stabilizing/augmenting fractured osteoporotic vertebral body fractures (for example, *via* vertebroplasty or balloon kyphoplasty)[73], and antibacterial coatings[74].

The present work focuses exclusively on the literature on AFAMBCs for long-term load-bearing TJA applications (as such, it excludes its use in spacers and blocks), giving a comprehensive and critical review of this body of knowledge by not only summarizing key results (with special emphasis on evaluations of antimicrobial efficacy and cytotoxicity) but, also, highlighting attractive features and shortcomings of literature studies. The latter feature should point to opportunities for future research in the field. This review should inform discussion of the potential for use of AFAMBCs to replace ALBCs.

**LITERATURE STUDIES**

***Antimicrobial activity***

The activity of a bone cement, in which the powder additive comprised NanoSilver particles (silver particles, of size 5-50 nm and porosity 85%-90%) (loading between 0% and 1%), when tested against a clinical isolate of MRSE showed loading dependency, with increased loading of the additive leading to increased activity; specifically, cement having a loading of 1% of the additive producing complete inhibition of proliferation of the bacterial strain. As a reference, uninhibited proliferation of the strain occurred when an approved ALBC brand (that contained 2% gentamicin) was used[50]. This same comparative trend was found when 1% NanoSilver-loaded cement was compared with the approved ALBC brand when a clinical isolate of *S. epidermidis* was used[50].

Chitosan (CS) nanoparticles (CS-NPs) (diameter: 220 ± 3 nm) were prepared using the ionic gelation method and quaternary ammonium chitosan (QCS) was synthesized by the method presented by Huh *et al*[75] QCS NPs (mean diameter: 284 ± 2 nm) were obtained from QCS in the same manner as was done for CS-NPs. Two approved plain ALBC brands and two approved ALBC brands were used as negative and positive control cements, respectively. Two sets of experimental AFAMBCs were formulated, one by adding CS-NPs to the cement powder and the other by adding QCS-NPs to the cement powder[51]. Against both *S. aureus* and *S. epidermidis*, each of the AFAMBCs showed significant improvement in antimicrobial activity compared to a control cement, but with QCS-NP-loaded cement showing significantly higher activity than the CS-NP-loaded cement[51]. These results were attributed to the fact that the NPs provide a high surface charge density for interacting with and disrupting bacterial cell membranes[51].

An experimental AFAMBC was obtained by mixing a monomer of quaternized ethylene glycol dimethacrylate piperazine octyl ammonium iodide (QAMA) into the liquid of an approved plain ALBC brand (10, 15, and 20 wt/wt%) (designated PMMA-10QAMA, PMMA-15QAMA, and PMMA-20QAMA cements, respectively)[52]. While *Escherichia coli* (*E. coli*) was retained on the surface of plain cement specimens, there was no evidence of retention and aggregation on experimental AFAMBC specimens. The antimicrobial action displayed by the AFAMBCs was attributed to the presence of QAMA, a polymerizable monomer that has an irreversibly bound component[52].

Using a novel synthesis route, Ag nanoparticles (AgNPs) with very well controlled geometrical properties and stability were obtained and, then, these particles were capped with tiopronin (TIOP), an agent that allows binding of other compounds to the nanoparticles[54]. These nanoparticles (AgNPs-TIOP) were added to the powder of a plain PMMA bone cement (0.1%, 0.5%, and 1.0%)[54]. Against gram-positive methicillin-resistant *S. aureus* (MRSA), the difference in growth rate of the bacterial strain when specimens of the experimental AFAMBC (1% of mean diameter 11 nm Ag-TIOP nanoparticles) and those of a control cement (no Ag nanoparticles) were used was not significant but the lag time (directly related to resistance to growth of the bacterial strain) of the AFAMBC was approximately 12 times longer than that the control cement specimens were used, indicating the better antimicrobial performance of the former cement[54]. Although the exact mechanism responsible for the antimicrobial activity of Ag nanoparticles has not been established, many explanations have been put forward. Examples are uptake of free Ag ions followed by disruption of the production of an energy storage molecule (adenosine triphosphate (ATP)) and replication of DNA[76]; inactivation of the bacterial cell (cell membrane and enzymes) by the Ag ions interfering with enzymes that interact with sulfur in the protein chains and/or generating reactive oxygen species[54], which kill the cells; and Ag ions causing separation of paired strands of DNA in the bacteria[77].

A bioactive glass (SiO2-Na2O-CaO-P2O5-B2O3-Al2O3-Ag2O) was produced by melting the reactants in a Pt crucible at 1450 oC, then quenching the melt in water to obtain a frit that was milled and sieved to yield glass powder (SBAG powder) (grain size < 20 mm)[55]. An experimental AFAMBC was obtained by mechanically mixing SBAG powder with the powder of an approved plain cement brand (loading: 30% and 50%), with two brands being used as control, one classified as low-viscosity (LV) and the other high-viscosity. Against *S. aureus*, a small drop in both proliferation and adhesion were observed when an AFAMBC rather than a control cement was used, with the same trends being seen in the values of the McFarland Index[55]. In an inhibition halo test, as expected, the size of the halo zone when AFAMBC specimens were used decreased with length of time of contact of the specimens with the agar substrate but, importantly, at the end of the 2nd day, the inhibition zone measured between approximately 1.0 and approximately 1.5 mm, indicating that the antibacterial capability of the cements is good[78,79]. The antimicrobial activity of a bioactive glass has been attributed to an increase of aqueous pH and osmolarity in the *in vivo* zone that surrounds the glass, which accompanies the dissolution of the glass[80], and deposition of glass debris on the surface of the bacteria[81].

Organic nanoparticles containing propylparaben were prepared by fast simultaneous removal of solvents and water from a volatile oil-in-water microemulsion composed of polypylparaben, *n*-butyl acetate, iso-propyl alcohol, sodium dodecyl sulfate (SDS), polyvinylpyrrolidone (PVP), and water, resulting in a fine powder composed of propylparaben nanoparticles (16 wt/wt%), SDS (45 wt/wt%), and PVP (39 wt/wt%)[56]. An AFAMBC was formulated by adding this fine powder to the powder of an experimental plain bone cement formulation (0.1%, 0.5%, 1%, 2%, 5%, and 7%). Overall, against a given bacterial strain (*S. aureus*, MRSA, or *S. epidermidis*), the duration of the lag phase increased but the growth rate (GR) decreased with increase in concentration of nanoparticles in the AFAMBC[56]. These trends suggest that the antimicrobial effect of the AFAMBC is a consequence of the conjoint reduction of viable microbial population and the viable cells not exhibiting the same phenotype of the cells in contact with the nanoparticles[56].

A modified Tollens method that involved reduction of AgNO3 to metal Ag by use of a glucose was used to synthesize Ag nanoparticles (AgNPs), which were then capped with oleic acid (OA) (Ag NPs-OA)[57]. These Ag NPs-OA were loaded into the powder of a plain PMMA bone cement (0.01, 0.05, and 0.10%)[57]. Against *S. aureus*, the mean duration of the lag phase (l) and the growth rate (GR) was between 5 and 6 times longer and between 2 and 3 lower on specimens of AFAMBC (0.05% AgNPs) compared to the corresponding values for plain cement (control cement) specimens, with the trend being the same when MRSA was used[57]. However, when *S. epidermidis* was used, the ratio for either l or GR was much smaller (approximately 1.4)[57].

An AFAMBC was formulated by mixing commercially-available Ag nanoparticles (diameter: 30-50 nm), which had been surface-functionalized with polyvinylpyrrolidone (0.2 wt/wt%) to aid dispersion and minimize agglomeration of the particles, into the liquid of an approved plain cement brand or an approved ALBC brand (loading ratio: 0.25%, 0.50%, and 1.0%, relative to mass of its powder) using an ultrasonic homogenizer with a solid Ti tip[58]. Using a modified Kirby-Bauer disk diffusion assay, it was found that against each of the bacterial strains used (commercially-available *S. aureus* and *S. epidermidis* and 4 clinical isolates obtained from patients with active PJIs (2 *S. aureus* and 2 *S. epidermidi*s)), none of the AFAMBCs demonstrated antimicrobial activity (that is, there was a large area of bacterial colony growth) while the positive control (an approved ALBC brand; antibiotic: gentamicin) exhibited large zones of inhibition (about 18-39 mm)[58]. Similar trends were found in the results of studies in which time-kill assays against planktonic bacteria were performed[58]. However, results of bacterial adhesion tests showed that each of the AFAMBCs significantly reduced biofilm formation relative to the plain cement[58]. These results suggest that while the AFAMBCs have no antimicrobial activity against planktonic bacteria, they have good potential for use in cases where prevention of bacterial adhesion is needed (for example, in primary TJAs)[58]. It is to be noted that: (1) Many of the bacteria commonly involved in PJI, such as *S. aureus*, produce a biofilm, which is a community of microorganisms embedded in an organic polymer that mainly is composed of polysaccharides, proteins, extracellular DNA and lipids, that adheres to an implant surface[82]; (2) A biofilm allows planktonic cells to change their mode of growth to the sessile form[82]; and (3) It is expected that a biofilm will protect the dividing bacteria from the action of an AFAMBC[82,83].

An experimental AFAMBC was formulated by adding a first-generation quaternary ammonium dendrimer of tripropylene glycol diacrylate (TPGDA G-1) to the liquid of a commercially-available plain bone cement (5, 10, 15, or 20 wt/wt%)[59]. Against a commercially-available *S. aureus* strain, the mean antimicrobial efficiencies of 5TPGDA cement and 10TPGDA cement were 45% and 100%, respectively, compared to a negligible amount for the plain cement counterpart[59]. The antimicrobial action ofthe quaternary ammonium dendrimer was attributed to it breaking the wall and membrane of the microorganism[59].

A bioactive glass (SiO2-Na2O-CaO-P2O5-B2O3-Al2O3) was produced by melting the reactants in a Pt crucible at 1450 oC for 1 h, then quenching the melt in water to obtain a frit that was milled and sieved to yield glass powder (SBA2 powder) (grain size < 20 mm)[60].This powder was then subjected to an optimized ion-exchange process in aqueous solution of AgNO3, after which the silver-doped powder was dried in air at 60 oC (Ag-SBA2 powder). The experimental AFAMBC was obtained by mechanically mixing 30 wt% of Ag-SBA2 powder with the powder of an approved plain cement brand (Ag-SBA2 cement), with three approved plain PMMA cement brands being used as controls. Against a commercially-available stock of *S. aureus*, 1) a significant drop in both proliferation and adhesion were observed when the AFAMBC rather than a control cement was used, trends that were also seen in the values of the McFarland Index; and 2) in an inhibition halo test (Kirby-Bauer test), the size of the halo zone when AFAMBC specimens were used was between approximately 2.5 and approximately 3.0 mm[60].

An AFAMBC was formulated by mixing commercially-available gold nanoparticles (Au NPs; 99.95% purity; diameter: 10-20 nm) with the powder of an approved plain bone cement brand (loading: 0.25, 0.50, and 1.00 wt/wt%)[61]. Against clinical isolates of MRSA, 1) live bacterial cells were reduced by up to approximately 55% on specimens of cement containing 1 wt/wt% Au NPs compared to specimens of the control cement (no loaded Au NPs); and 2) three-dimensional reconstruction of the biofilm showed a drop of biofilm thickness by approximately 74% when an ALAMBC was used[61].

A bioactive glass (SiO2-Na2O-CaO-P2O5-B2O3-Al2O3) was produced by melting the reactants in a. Pt crucible at 1450 oC for 1 h, then quenching the melt in water to obtain a frit that was milled and sieved to yield glass powder (SBA3 powder) (diameter < 20 mm)[62]. This powder was then subjected to an optimized ion-exchange process in a copper-containing aqueous solution, after which the Cu-doped powder was washed, filtered, and dried in air at 60 oC (Cu-SBA3 powder). An experimental AFAMBC was obtained by mechanically mixing 10 wt% of Cu-SBA3 powder with the powder of an approved plain cement brand, with three approved plain PMMA cement brands being used as controls[62]. Against *S. epidermidis* biofilm, a significant drop in bacteria viability was observed at each assayed time-point when an AFAMBC rather than a control cement was used (by a factor of between 2 and 4), indicating that the antibacterial potential of the AFAMBC is good[62]. The antibacterial action of the Cu-SBA3 cements was explained in terms of participation of reactive hydroxyl radicals that are generated in reactions that are harmful to cellular molecules, such as oxidation of proteins[77]. Notwithstanding these results, the resistance of some bacterial species, such as *E. coli*, against copper-containing biomaterials, was noted[62].

A bioactive glass (SiO2-Na2O-CaO-P2O5-B2O3-Al2O3) was produced by melting the reactants in a Pt crucible at 1450 oC, then the melt was quenched in water to obtain a frit that was milled and sieved to yield glass powder (SBA2 powder) (grain size < 20 mm or 20-45 mm)[63]. This powder was subjected to an optimized ion-exchange process in aqueous solution of AgNO3, after which the silver-doped powder was dried in air and stored (Ag-SBA2 powder). An experimental AFAMBC was obtained by mechanically mixing 15 or 20 wt% of an Ag-SBA2 powder with the powder of an approved plain cement brand. Several combinations of process variables for producing the powder (drying temperature, storage mode, and mixing temperature) were used, resulting in 8 variants of powders. In an inhibition halo test in which a commercially-available *S. aureus* strain was used, the size of the halo zone when AFAMBC specimens were used was between approximately 2 and approximately 4 mm, indicating marked antibacterial activity of these cements[63].

An AFAMBC was prepared by incorporating sheets of CS and/or graphene oxide (GO) nanosheets, synthesized using the protocols given by Mangadlao *et al*[84], into the liquid of an experimental plain PMMA bone cement (CS- and GO-based cements)[64-66]. A plain cement served as the control cement. Against a commercially-available *S. aureus* strain, after 24 h incubation, the cements containing 0.2% GO (ABC-0.2GO cement), 0.3% GO (ABC-0.3GO cement), 0.5% GO (ABC-0.5GO cement), or 15% CS (ABC-15CS cement) showed significantly higher antimicrobial activity compared to that of the control cement[64,65]. Two mechanisms were postulated to explain the antimicrobial activity of the GO-based cement[64]. First, GO sheets directly contact the bacterial cell, thereby damaging them. Second, reactive oxygen species that are produced destroy the cell membrane subsequent to the GO sheets contacting the surface[64,65]. Synergistic antimicrobial activity was demonstrated in the cement that contained 0.5% GO and 15% CS (ABC-0.5GO-15CS cement)[64].

An experimental AFAMBC formulation (PMMA-NAC cement) was obtained by adding N-acetylcysteine powder (NAC) (an antibacterial agent) to PMMA bone cement in loadings ranging from 10 to 50% wt/vol[67]. At NAC loading ≥ 20% wt/vol, the antibacterial efficacy of the NAC-PMMA cement against planktonic forms of *S. aureus* and *E. coli* was significantly greater than that of the control cement (an approved plain cement brand). The same trend was seen against biofilm forms of the same bacterial strains.

Two variants of an experimental AFAMBC were prepared, the first one by mixing particles of a 5 wt/wt% of a bioglass (BGII-0.4; grain size: ≥ 40 mm), Ag NP powder (particle size: approximately 50 nm) (1.5 wt/wt%), and the powder of an approved plain cement brand (BC-BGII-0.4-AgNP cement)[68]. BGII-0.4 was prepared using the Stober method modified by Zheng *et al*[85]. The composition of the other variant was the same that of the first one with the exception that a different bioglass was used (a sol-gel obtained SiO2/CaO (70/30 mol%) bioglass; grain size: about 300 nm) (BG-MP)[68]). The antibacterial performance of each of the AFAMBC variants was determined in two tests using a hospital strain of *S. aureus*: inhibition of the growth of the strain after 4 h and effectiveness (methicillin resistance). In each of these tests, the BC-BGII-0.4-AgNP cement showed significant improvement compared to the control cement (an approved plain cement brand)[68].

***In vitro cytotoxicity/cytocompatibility***

On L929 mouse fibroblasts, the difference in release of lactate dehydrogenase (an indicator of cell integrity) when an experimental AFAMBC (NanoSilver-loaded cement) was used *vs* when an approved ALBC (control cement) was used, in a non-toxic cell culture medium, was not significant, a trend that was also observed both with protein content and number of vital cells, all of which showed that the lack of cytotoxicity of the AFAMBC[50]. Furthermore, on a human osteoblast cell line (hFOB), only a few dead osteoblasts were seen in live-dead staining in the NanoSilver bone cement specimens and osteoblasts that grew on these specimens were, in the main, vital and grew in a mesh-like manner, as just as in the cell culture medium, showing that the cement has high biocompatibility[50]. The results were explained in terms of Ag ions binding to cellular structures in the bacterial strain (especially, to their SH- groups), thereby interfering with the integrity, energy production, and conservation of the bacterial cell[50]. In contrast, bacterial resistance to the antibiotic in the control cement (gentamicin), being an aminoglycoside, can be acquired by single point mutations [50].

On mouse fibroblast cells (3T3), the difference in cytotoxicity between an experimental AFAMBC (15% CS-NPs or 15% QCS-NPs added to cement powder) and a negative control cement was not significant[51]. There was good adherence of cells (a commercially-available human osteosarcoma cell line; HOS TE85) on specimens of PMMA-15QAMA cement after 1 wk, indicating cytocompatibility of the cement[52].

On osteoblast cells (MC 3TC), the difference in cytotoxicity between the Ag nanoparticles-tiopronin cement and the control cement (an approved plain ALBC brand) was not significant, regardless of the nanoparticles loading of the cement[54].

On osteoblast cells (MC-3T3), the difference in cytotoxicity between an experimental AFAMBC (contained Ag NPs-TIO) and a counterpart control cement (same composition but no Ag NPs-TIO) was not significant regardless of the duration of exposure to the cells[56]. On osteoblast cells (MC-3T3), the difference in cytotoxicity between an experimental AFAMBC (contained the Ag NPs-OA) and the control cement (plain PMMA cement) was not significant, regardless of the nanoparticles loading of the cement[57]. On Jukrat cells (T-lymphocyte), an experimental AFAMBC (10TPGDA-G1 cement) was significantly less cytotoxic than a counterpart cement (same composition but no TPGDA)[59]. Using a continuous mouse fibroblast cell line (L-929; BS-CL-56), an experimental AFAMBC (Ag-SBA2 cement) was not cytotoxic and the difference in the viability of the cells on the cement and that of its plain counterpart cement was not significant[60].

On human osteoblast (HOb) cells, none of three experimental AFAMBCs (ABC-0.3GO, ABC-15CS, and ABC-0.3GO-15CS cements) showed cytotoxicity because the cellular viability in the presence of extracts taken between 1 d and 7 d increased with time and was > 90%[64]. When HOb was directly seeded on the surfaces of the specimens of each of the AFAMBCs, enhanced surface colonization and proliferation at the early stages (1 and 4 d) was obtained, compared to the case when specimens of plain ABC (control cement) were used[64]. The trends found in this work were also observed when the culture times were 14 d and 21 d[66]. In other words, in each of the AFAMBCs, GO and CS exerted desirable effects on cell adhesion, proliferation, and deposition[66]. These results are consistent with GO increasing the hydrophilicity of the cement surface, thereby allowing easy anchoring of hydroxyl groups to the surface of the cell[86] and the low toxicity of CS and its excellent ability to promote osteoblastic cell growth[87]. After cement immersion for 1 wk, PMMA-NAC cement with NAC loading about 30% wt/vol was significantly less toxic to human fibroblasts, human osteoblasts, and chondrocytes than was the case with control cement (an approved plain cement brand)[67].

The viability of periodontal ligament cells after 7 d of culture on BC-BGII-0.4-AgNP cement was significantly less than on control cement (an approved plain cement brand), with the same trend found for BC-BG-MP-AgNp cement[68]. In general, the results showed that the cytocompatibility of the BC-modified cement is a complex phenomenon, with relevant factors including, but not limited to, the amount of MMA released by a cement, bioactivity of the cement, and amount of BG[68].

***Summary of antimicrobial activity and cytotoxicity/cytocompatibility results***

The results of the studies summarized in the preceding two sub-sections provide ample evidence that, against micro-organisms that have been commonly found in PJI cases, an AFAMBC has excellent antimicrobial activity and is not cytotoxic and, by extension, has excellent biocompatibility and bioadherence. The first two mentioned characteristics translate to achievement of antimicrobial efficacy being achieved with a very small amount of an AFAMBC. The last-mentioned characteristics indicate that an AFAMBC limits the adherence of planktonic-forming bacteria on an implant surface, which is the first step in biofilm formation[82,83].

***Other cement properties***

The number of studies in which other cement properties were determined varied widely, from fewer than 5 (example properties: tensile modulus, tensile strength, fracture toughness, and radiopacity) to more than 20 (property: compressive strength) (Table 1). Among these results, there is clear evidence that for an AFAMBC, its maximum polymerization temperature is lower (which is desirable, because it lowers the potential for thermal necrosis of periprosthetic tissue), setting time is longer (which is not desirable, because it increases TJA surgery time), compressive strength and flexural modulus are each comparable (both of which indicate that the load-bearing ability of an implant anchored using either an ALBC or an AFAMBC would be comparable) and cell viability is higher (which is desirable because it indicates increased cell survival in the presence of an AFAMBC), relative to corresponding values for the control cement (which, in all but two studies, was a plain cement, that is one in which there was no antimicrobial additive). However, the trend in each of the other cement properties determined is unclear.

**CRITICAL APPRAISAL OF THE LITERATURE**

With reference to clinically-relevant properties other than those discussed in the previous Section, the literature has a few attractive features but many shortcomings.

***Attractive features***

First, the surfaces of specimens of formulated AFAMBCs have been extensively characterized, using an assortment of methods, such as scanning electron microscopy without and with energy dispersion spectroscopy[52,55,58-60,62-66],transmission electron microscopy[54], x-ray diffraction[55], Fourier transform infrared spectroscopy[58,59,64,65], x-ray photoelectron spectroscopy[58], atomic force microscopy[57,64], and Raman spectroscopy[64]. One noteworthy result from these characterization studies is that distribution of the GO in a GO-based AFAMBC, obtained using Raman mapping, showed that GO is well distributed within the cement matrix[64], which, it was suggested, will enhance mechanical properties of the AFAMBC[64].

Second, the literature contains a large assortment of *in vitro* properties of the formulated ALAMBCs, ranging from release of the antimicrobial agent and its activity against *S. aureus* to cytocompatibility against human osteoblast cell line and water uptake. In this regard, the studies by Prokopovich *et al*[57] and by Russo *et al*[61**]** merit special mention because their studies illuminate subtle differences in the mechanical behavior of AFABCs and their control cement counterparts. In the Prokopovich *et al*[57] study,near-surface values of elastic modulus were determined using a quasi-static nanoindentation technique (atomic force microscopy). One key finding was that for specimens conditioned in PBS, at 37 oC, for 4 wk before the test, the elastic moduli at the surface and the bulk of a specimen were about the same, regardless of whether the cement was an AFAMBC or its control cement counterpart (no antibacterial agent added). Russo *et al*[61] performed small punch tests on miniature disk-shaped cement specimens. The load-displacement curves obtained displayed an initial linear zone, followed by a decrease in slope, achievement of a peak load (Ppeak), and, finally, a drop in load until fracture occurs. The results showed that Ppeak for an AFAMBC with low loading (0.25% Au NPs) was significantly higher than that of the control cement but, with an AFAMBC that has a higher loading (0.5% and 1.0% Au NPs), Ppeak was lower than that of the control cement. These results are consistent with the postulate that with high Au NP loading, either NP clusters form, which act as weak features, and/or a different ductility exists between the cement matrix and the Au NPs, which acts to weaken the cement by creating stress risers and discontinuities at the matrix-Au NPs interface[61].

Third,in a few studies, an additive used to formulate an AFAMBC bestowed an additional benefit of bioactivity to the cement. Lack of bioactivity (and, hence, poor osseointegration) is one of the shortcomings of ALBCs[20]. The aforementioned additives were the powder of a bioactive glass, chitosan, and graphene oxide nanosheets[55,60,62-66]. After 7-28 d of immersion of specimens of bioactive glass powder-loaded cement in simulated body fluid, at 37 oC, there was evidence of agglomerates on the specimen surface that were rich in calcium and phosphorus (hydroxyapaptite (HaP)) (Ca/P ratio = approximately 0.9 to approximately 4.0)[60,62,63]. Among other actions, Ca and P ions combine with local ions to form a HaP-like layer on the surface of components of a TJA, which enhances the ability of the surface to bond with both soft and hard tissues[88]. Furthermore, these agglomerates exhibited the globular morphology that was typical of HaP grown on the surfaces of biomaterial specimens[60,62,63].

***Shortcomings***

First,with only two exceptions[51,53], an ALBC was not used as the control cement in the studies. This means that comments cannot be made on the potential for AFAMBCs to replace ALBCs in clinical practice.

Second,in some studies, the plain cement that was used as the control contained a constituent that is not part of the composition of any approved plain cement brand (or, indeed, any approved ALBC brand); specifically, 2-(diethylamino) ethyl acrylate (DEAEA), and 2-(diethylamino) ethyl methacrylate (DEAEM) in the liquid[64-66].

Third, there was only one study in which, for the preparation of the cement dough, the powder (with or without antimicrobial additive(s)) and the liquid (with or without antimicrobial additive) were mixed under vacuum[50]. In all the other studies, the mixing method was either manual[51,52,54-56,59,64-66,68] or a mechanical mixer was used[62]; or, else, the mixing method used was not explicitly stated[57,60,61,63,66]. It is well known that mixing method exerts a significant influence on the properties of curing and cured properties of PMMA bone cement[20].

Fourth, in the evaluation of the antimicrobial activity of the cements, a clinical/hospital strain of microorganisms that are commonly found in PJI cases (such as *S. aureus* and *S. epidermidis*) was used in only two studies[50,68]. More importantly,invery few studies was a biofilm utilized in the evaluation of antimicrobial activity of the cements[50,62]. This situation is unfortunate given universal acknowledgement that PJI is a form of biofilm-associated implant-related musculoskeletal infection[34,82,83,89-91]; specifically, there is a “race to the top” in which the released antibiotic is inefficacious if a biofilm forms on the surface of the implant before the released antimicrobial agent gets there[92-94].

Fifth, in only a few studies was a human cell line used in the evaluation of cytotoxicity of the cements[50,52,64-66,68]. To give studies clinical relevance, use of a human cell line is preferred to use of cell lines from animals, such as mouse fibroblast.

Sixth, determination of release of the antimicrobial agent from an AFAMBC was conducted in fewer than 30% of studies [54-57,60,62]. Comparing and contrasting the details of this profile to that from an ALBC counterpart[25] would have provided information that may be useful in the design of future AFAMBCs.

Seventh, *in vivo* evaluation of AFAMBCs have been performed in only two studies. In the first, the cements compared were an approved plain bone cement brand (PBC), two experimental cement formulations (an approved plain bone cement brand loaded with 0.6 or 1.0 wt/wt% Nanosilver) (EAGC)), and an approved ALBC brand (antibiotic: tobramycin) (TOBC)[53]. Into the medullary canal of the right femur of female New Zealand White rabbits was injected a cement dough after contamination with a commercially-available *S. aureus* strain[53]. After 14 d, 100% incidence of *S. aureus* was found in all the rabbits in which either PBC or EAGC used, whereas, when TOBC was used, the incidence was 17% (2 out of the 12 rabbits). These results suggest that EAGC may not be suitable for use in revision TJA, where bacteria are already in the periprosthetic tissues[53]. In the second study[66], a dough of the cement (plain, ABC-0.3GO, ABC-15CS, or ABC-0.3GO-15CS cements) was injected into 5 mm-diameter defect created in the parietal bone of Wistar rats (age and mean mass = 8 mo and 0.37 kg, respectively)[66]. After 3 mo of implantation, higher amounts of osseointegration and biocompatibility were obtained with each of the experimental AFAMBC formulations (ABC-0.3GO, ABC-15CS, and ABC-0.3GO-15CS) compared to the corresponding values when the plain bone cement brand was used[66].

Eighth, the quality of the statistical analysis of results presented in the reports was variable. In four reports, there was no mention that statistical analysis was performed[50,59,60,63] even though, in one of them, it was stated that there was “no significant difference in quantitative cytotoxicity testing between the NanoSilver bone cement and the non-toxic control group”[50]. In the vast majority of studies, a parametric test of comparison (Student *t*-test, or ANOVA) was used for intergroup comparisons[51,52,54-57,61,62,64-66]. In only two reports (those by Slane *et al*[58] and by Wekwejt *et al*[68]**)** was the correct methodology used; that is, test for normality and homogeneity of variance of the datasets was conducted before a parametric test of comparison was applied.

**FUTURE PROSPECTS**

The shortcomings of the literature, as expounded on in the immediately preceding Section, together with other considerations, lead to identification of potential areas for future research. Four are presented here.

First, detailed studies should be performed on the influence of an AFAMBC on the ability of bacteria to form biofilm on surfaces of alloys currently used to fabricate parts of TJA, such as the stem of a total hip arthroplasty (for example, Ti-6Al-4V and Co-Cr-Mo[95], and those proposed for such use (for example, Ti-34Nb-2Ta-0.5O[96], Ti-12Nb-12Zr-12Sn[97], Ti-13Nb-13Zr[98], 40Ti-60Ta composite[99], Ti-39Nb-6Zr-0.45Al[100], and cold groove-rolled Ti-35Nb-3.75Sn[101]). Specifically, these studies should focus on determining the effectiveness of an AFAMBC vis a vis biofilms; that is, the extent to which an AFAMBC: (1) Inhibits microbial adhesion to the surface and colonization; (2) Interferes with the signal molecules that modulate biofilm formation (and associated increased antibiotic tolerance) (for example, quorum sensing inhibitors and/or quorum quenching agents[102-105]; and (3) Disaggregates the biofilm matrix[89,90,92,93,104-110].

Second, studies should be conducted to determine cement properties that have been the subject of only a few studies, such as radiopacity, fracture toughness, and liquid contact angle (q), or have not been determined, examples being fatigue performance (fatigue life and/or fatigue strength), fatigue crack growth/propagation rate, and creep. With regard to q, it should be determined using a biosimulating solution, such as PBS or simulated body fluid, rather than water, as has been the case[59,68]. Fatigue performance should be determined following the method stipulated in the relevant bone cement testing standard (ASTM F2118 or ISO 16402[111,112]).

Third, there are number of novel antimicrobial materials that should be investigated for their suitability to be formulated into a suitable form to be used as additives for an AFAMBC. Examples of materials that could be added to the powder of a plain cement are a quorum-sensing inhibitor drug[113], Ti-doped ZnO[114], nano-GO nanosheets[115], selenium nanoparticles[116], Ag-nanoparticle-reduced GO nanocomposite[117], chitosan hybrid nanoparticles[118], a Cu cluster molecule[119], powder prepared from extract from a Tunisian lichen[120], Yb-doped ZnO nanoparticles[121], and an analog of PKZ18 (PKZ18-22), a molecule that has been shown to block growth of antibiotic-resistant *S. aureus* in biofilm[122].Examples of materials that could be added to the liquid of a plain cement are benzothiazole or one of its derivatives[123,124] and a natural antimicrobial agent (such as extract of *Salvadora persica*, *Olea europaea*, and *Ficus carcia* leaves[125] or biosynthesized ZnO nanoflowers[126]).

Fourth, in all studies, the control cement must be an ALBC, preferably an approved ALBC brand. This will ensure that the results of property determinations will be used as a basis for making a recommendation on the clinical use of an AFAMBC instead of an ALBC.

**ACKNOWLEDGEMENTS**

The author thanks Attarzardeh F, Department of Mechanical Engineering, University of Memphis, for formatting the list of references and the table.

**REFERENCES**

1 **Dale H**, Fenstad AM, Hallan G, Havelin LI, Furnes O, Overgaard S, Pedersen AB, Kärrholm J, Garellick G, Pulkkinen P, Eskelinen A, Mäkelä K, Engesæter LB. Increasing risk of prosthetic joint infection after total hip arthroplasty. *Acta Orthop* 2012; **83**: 449-458 [PMID: 23083433 DOI: 10.3109/17453674.2012.733918]

2 **Kurtz SM**, Lau EC, Son MS, Chang ET, Zimmerli W, Parvizi J. Are We Winning or Losing the Battle With Periprosthetic Joint Infection: Trends in Periprosthetic Joint Infection and Mortality Risk for the Medicare Population. *J Arthroplasty* 2018; **33**: 3238-3245 [PMID: 29914821 DOI: 10.1016/j.arth.2018.05.042]

3 **Kapadia BH**, McElroy MJ, Issa K, Johnson AJ, Bozic KJ, Mont MA. The economic impact of periprosthetic infections following total knee arthroplasty at a specialized tertiary-care center. *J Arthroplasty* 2014; **29**: 929-932 [PMID: 24140271 DOI: 10.1016/j.arth.2013.09.017]

4 **Kühn KD (2017) Management of periprosthetic joint infection: A global perspective on diagnosis,** treatment options, prevention strategies and their economic impact. Springer, Berlin.

5 **Jämsen E**, Nevalainen P, Eskelinen A, Huotari K, Kalliovalkama J, Moilanen T. Obesity, diabetes, and preoperative hyperglycemia as predictors of periprosthetic joint infection: a single-center analysis of 7181 primary hip and knee replacements for osteoarthritis. *J Bone Joint Surg Am* 2012; **94**: e101 [PMID: 22810408 DOI: 10.2106/JBJS.J.01935]

6 **Meehan JP**, Danielsen B, Kim SH, Jamali AA, White RH. Younger age is associated with a higher risk of early periprosthetic joint infection and aseptic mechanical failure after total knee arthroplasty. *J Bone Joint Surg Am* 2014; **96**: 529-535 [PMID: 24695918 DOI: 10.2106/JBJS.M.00545]

7 **Otto-Lambertz C**, Yagdiran A, Wallscheid F, Eysel P, Jung N. Periprosthetic Infection in Joint Replacement. *Dtsch Arztebl Int* 2017; **114**: 347-353 [PMID: 28610654 DOI: 10.3238/arztebl.2017.0347]

8 **Tubb CC**, Polkowksi GG, Krause B. Diagnosis and Prevention of Periprosthetic Joint Infections. *J Am Acad Orthop Surg* 2020; **28**: e340-e348 [PMID: 31972719 DOI: 10.5435/JAAOS-D-19-00405]

9 **Love C**, Marwin SE, Tomas MB, Krauss ES, Tronco GG, Bhargava KK, Nichols KJ, Palestro CJ. Diagnosing infection in the failed joint replacement: a comparison of coincidence detection 18F-FDG and 111In-labeled leukocyte/99mTc-sulfur colloid marrow imaging. *J Nucl Med* 2004; **45**: 1864-1871 [PMID: 15534056]

10 **McNally M**, Sousa R, Wouthuyzen-Bakker M, Chen AF, Soriano A, Vogely HC, Clauss M, Higuera CA, Trebše R. The EBJIS definition of periprosthetic joint infection. *Bone Joint J* 2021; **103-B**: 18-25 [PMID: 33380199 DOI: 10.1302/0301-620X.103B1.BJJ-2020-1381.R1]

11 **Lee YS**, Lee YK, Han SB, Nam CH, Parvizi J, Koo KH. Natural progress of D-dimer following total joint arthroplasty: a baseline for the diagnosis of the early postoperative infection. *J Orthop Surg Res* 2018; **13**: 36 [PMID: 29439725 DOI: 10.1186/s13018-018-0730-4]

12 **Tirumala V**, Klemt C, Xiong L, Chen W, van den Kieboom J, Kwon YM. Diagnostic Utility of Platelet Count/Lymphocyte Count Ratio and Platelet Count/Mean Platelet Volume Ratio in Periprosthetic Joint Infection Following Total Knee Arthroplasty. *J Arthroplasty* 2021; **36**: 291-297 [PMID: 32773272 DOI: 10.1016/j.arth.2020.07.038]

13 **Li R**, Li X, Ni M, Zheng QY, Zhang GQ, Chen JY. Anatomic Landmark-Guided Hip Aspiration in the Diagnosis of Periprosthetic Joint Infection. *Orthopedics* 2021; **44**: e85-e90 [PMID: 33089335 DOI: 10.3928/01477447-20201007-04]

14 **Vaz K**, Scarborough M, Bottomley N, Kendrick B, Taylor A, Price A, Alvand A, Jackson W. Debridement, antibiotics and implant retention (DAIR) for the management of knee prosthetic joint infection. *Knee* 2020; **27**: 2013-2015 [PMID: 32950374 DOI: 10.1016/j.knee.2020.08.011]

15 **Zhu MF**, Kim K, Cavadino A, Coleman B, Munro JT, Young SW. Success Rates of Debridement, Antibiotics, and Implant Retention in 230 Infected Total Knee Arthroplasties: Implications for Classification of Periprosthetic Joint Infection. *J Arthroplasty* 2021; **36**: 305-310.e1 [PMID: 32868114 DOI: 10.1016/j.arth.2020.07.081]

16 **Aggarwal VK**, Rasouli MR, Parvizi J. Periprosthetic joint infection: Current concept. *Indian J Orthop* 2013; **47**: 10-17 [PMID: 23531512 DOI: doi:]

17 **Osmon DR**, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR; Infectious Diseases Society of America. Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* 2013; **56**: 1-10 [PMID: 23230301 DOI: 10.1093/cid/cis966]

18 **Kunutsor SK**, Whitehouse MR, Blom AW, Board T, Kay P, Wroblewski BM, Zeller V, Chen SY, Hsieh PH, Masri BA, Herman A, Jenny JY, Schwarzkopf R, Whittaker JP, Burston B, Huang R, Restrepo C, Parvizi J, Rudelli S, Honda E, Uip DE, Bori G, Muñoz-Mahamud E, Darley E, Ribera A, Cañas E, Cabo J, Cordero-Ampuero J, Redó MLS, Strange S, Lenguerrand E, Gooberman-Hill R, Webb J, MacGowan A, Dieppe P, Wilson M, Beswick AD; Global Infection Orthopaedic Management Collaboration. One- and two-stage surgical revision of peri-prosthetic joint infection of the hip: a pooled individual participant data analysis of 44 cohort studies. *Eur J Epidemiol* 2018; **33**: 933-946 [PMID: 29623671 DOI: 10.1007/s10654-018-0377-9]

19 **Kildow BJ**, Della-Valle CJ, Springer BD. Single vs 2-Stage Revision for the Treatment of Periprosthetic Joint Infection. *J Arthroplasty* 2020; **35**: S24-S30 [PMID: 32046827 DOI: 10.1016/j.arth.2019.10.051]

20 **Lewis G**. Properties of antibiotic-loaded acrylic bone cements for use in cemented arthroplasties: a state-of-the-art review. *J Biomed Mater Res B Appl Biomater* 2009; **89**: 558-574 [PMID: 18823020 DOI: 10.1002/jbm.b.31220]

21 **Kühn KD**, Höntzsch D. [Augmentation with PMMA cement]. *Unfallchirurg* 2015; **118**: 737-748 [PMID: 26315391 DOI: 10.1007/s00113-015-0059-y]

22 **Villa JM**, Pannu TS, Theeb I, Buttaro MA, Oñativia JI, Carbo L, Rienzi DH, Fregeiro JI, Kornilov NN, Bozhkova SA, Sandiford NA, Piuzzi NS, Higuera CA, Kendoff DO. International Organism Profile of Periprosthetic Total Hip and Knee Infections. *J Arthroplasty* 2021; **36**: 274-278 [PMID: 32828620 DOI: 10.1016/j.arth.2020.07.020]

23 **Lewis G**, Brooks JL, Courtney HS, Li Y, Haggard WO. An Approach for determining antibiotic loading for a physician-directed antibiotic-loaded PMMA bone cement formulation. *Clin Orthop Relat Res* 2010; **468**: 2092-2100 [PMID: 20195806 DOI: 10.1007/s11999-010-1281-0]

24 Lewis G Antibiotic release enhancement methods for antibiotic-loaded PMMA bone cement for periprosthetic joint infection prophylaxis in cemented total joint arthroplasties: current status and future prospects. Journal of Materials Science Research and Reviews 2020; 6: 1-21.https://journaljmsrr.com/index.php/JMSRR/article/view/30160. Accessed 18 Nov 2021

25 **Mensah LM**, Love BJ. A meta-analysis of bone cement mediated antibiotic release: Overkill, but a viable approach to eradicate osteomyelitis and other infections tied to open procedures. *Mater Sci Eng C Mater Biol Appl* 2021; **123**: 111999 [PMID: 33812619 DOI: 10.1016/j.msec.2021.111999]

26 **Cummins JS**, Tomek IM, Kantor SR, Furnes O, Engesaeter LB, Finlayson SR. Cost-effectiveness of antibiotic-impregnated bone cement used in primary total hip arthroplasty. *J Bone Joint Surg Am* 2009; **91**: 634-641 [PMID: 19255224 DOI: 10.2106/JBJS.G.01029]

27 **Qadir R**, Sidhu S, Ochsner JL, Meyer MS, Chimento GF. Risk stratified usage of antibiotic-loaded bone cement for primary total knee arthroplasty: short term infection outcomes with a standardized cement protocol. *J Arthroplasty* 2014; **29**: 1622-1624 [PMID: 24703363 DOI: 10.1016/j.arth.2014.02.032]

28 **Yi Z**, Bin S, Jing Y, Zongke Z, Pengde K, Fuxing P. No decreased infection rate when using antibiotic-impregnated cement in primary total joint arthroplasty. *Orthopedics* 2014; **37**: 839-845 [PMID: 25437076 DOI: 10.3928/01477447-20141124-07]

29 **Sanz-Ruiz P**, Matas-Diez JA, Sanchez-Somolinos M, Villanueva-Martinez M, Vaquero-Martín J. Is the Commercial Antibiotic-Loaded Bone Cement Useful in Prophylaxis and Cost Saving After Knee and Hip Joint Arthroplasty? The Transatlantic Paradox. *J Arthroplasty* 2017; **32**: 1095-1099 [PMID: 27919578 DOI: 10.1016/j.arth.2016.11.012]

30 **King JD**, Hamilton DH, Jacobs CA, Duncan ST. The Hidden Cost of Commercial Antibiotic-Loaded Bone Cement: A Systematic Review of Clinical Results and Cost Implications Following Total Knee Arthroplasty. *J Arthroplasty* 2018; **33**: 3789-3792 [PMID: 30217400 DOI: 10.1016/j.arth.2018.08.009]

31 **Bendich I**, Zhang N, Barry JJ, Ward DT, Whooley MA, Kuo AC. Antibiotic-Laden Bone Cement Use and Revision Risk After Primary Total Knee Arthroplasty in U.S. Veterans. *J Bone Joint Surg Am* 2020; **102**: 1939-1947 [PMID: 32890041 DOI: 10.2106/JBJS.20.00102]

32 **Namba RS**, Prentice HA, Paxton EW, Hinman AD, Kelly MP. Commercially Prepared Antibiotic-Loaded Bone Cement and Infection Risk Following Cemented Primary Total Knee Arthroplasty. *J Bone Joint Surg Am* 2020; **102**: 1930-1938 [PMID: 32826555 DOI: 10.2106/JBJS.19.01440]

33 **Pellegrini AV**, Suardi V. Antibiotics and cement: what I need to know? *Hip Int* 2020; **30**: 48-53 [PMID: 32290707 DOI: 10.1177/1120700020915463]

34 **Schwarz EM**, McLaren AC, Sculco TP, Brause B, Bostrom M, Kates SL, Parvizi J, Alt V, Arnold WV, Carli A, Chen AF, Choe H, Coraça-Huber DC, Cross M, Ghert M, Hickok N, Jennings JA, Joshi M, Metsemakers WJ, Ninomiya M, Nishitani K, Oh I, Padgett D, Ricciardi B, Saeed K, Sendi P, Springer B, Stoodley P, Wenke JC; Hospital for Special Surgery 2019 Biofilm Symposium Workgroup. Adjuvant antibiotic-loaded bone cement: Concerns with current use and research to make it work. *J Orthop Res* 2021; **39**: 227-239 [PMID: 31997412 DOI: 10.1002/jor.24616]

35 **Sebastian S**, Liu Y, Christensen R, Raina DB, Tägil M, Lidgren L. Antibiotic containing bone cement in prevention of hip and knee prosthetic joint infections: A systematic review and meta-analysis. *J Orthop Translat* 2020; **23**: 53-60 [PMID: 32489860 DOI: 10.1016/j.jot.2020.04.005]

36 **Farhan-Alanie MM**, Burnand HG, Whitehouse MR. The effect of antibiotic-loaded bone cement on risk of revision following hip and knee arthroplasty. *Bone Joint J* 2021; **103-B**: 7-15 [PMID: 33380204 DOI: 10.1302/0301-620X.103B1.BJJ-2020-0391.R1]

37 **Jiranek WA**, Hanssen AD, Greenwald AS. Antibiotic-loaded bone cement for infection prophylaxis in total joint replacement. *J Bone Joint Surg Am* 2006; **88**: 2487-2500 [PMID: 17079409 DOI: 10.2106/JBJS.E.01126]

38 **Wilairatana V**, Sinlapavilawan P, Honsawek S, Limpaphayom N. Alteration of inflammatory cytokine production in primary total knee arthroplasty using antibiotic-loaded bone cement. *J Orthop Traumatol* 2017; **18**: 51-57 [PMID: 27770338 DOI: 10.1007/s10195-016-0432-9]

39 **Hansen EN**, Adeli B, Kenyon R, Parvizi J. Routine use of antibiotic laden bone cement for primary total knee arthroplasty: impact on infecting microbial patterns and resistance profiles. *J Arthroplasty* 2014; **29**: 1123-1127 [PMID: 24418770 DOI: 10.1016/j.arth.2013.12.004]

40 **Sinclair KD**, Pham TX, Farnsworth RW, Williams DL, Loc-Carrillo C, Horne LA, Ingebretsen SH, Bloebaum RD. Development of a broad spectrum polymer-released antimicrobial coating for the prevention of resistant strain bacterial infections. *J Biomed Mater Res A* 2012; **100**: 2732-2738 [PMID: 22623404 DOI: 10.1002/jbm.a.34209]

41 **Jennings JA**, Carpenter DP, Troxel KS, Beenken KE, Smeltzer MS, Courtney HS, Haggard WO. Novel Antibiotic-loaded Point-of-care Implant Coating Inhibits Biofilm. *Clin Orthop Relat Res* 2015; **473**: 2270-2282 [PMID: 25604874 DOI: 10.1007/s11999-014-4130-8]

42 **Ozcelik B**, Ho KKK, Glattauer V, Willcox M, Kumar N, Thissen H. Poly(ethylene glycol)-Based Coatings Combining Low-Biofouling and Quorum-Sensing Inhibiting Properties to Reduce Bacterial Colonization. *ACS Biomater Sci Eng* 2017; **3**: 78-87 [PMID: 33429684 DOI: 10.1021/acsbiomaterials.6b00579]

43 **Tobin EJ**. Recent coating developments for combination devices in orthopedic and dental applications: A literature review. *Adv Drug Deliv Rev* 2017; **112**: 88-100 [PMID: 28159606 DOI: 10.1016/j.addr.2017.01.007]

44 **Han X,** Ji X, Zhao M, Li D. Mg/Ag ratios induced in vitro cell adhesion and preliminary antibacterial properties of TiN on medical Ti-6Al-4V alloy by Mg and Ag implantation. Surf Coat Technol 2020; 397: 126020 [DOI:10.1016/j.surfcoat.2020.126020]

45 **Kharat Z,** Sadri M, Kabiri M. Herbal extract loaded chitosan/PEO nanocomposites as antibacterial coatings of orthopaedic implants.Fibers Polym 2021; 22: 989-999 [DOI:10.1007/s12221-021-0490-3]

46 **Sivakumar B**, Vijaysegaran P, Chaudhuri A, Crawford S, Ottley M. Daptomycin resistance in prosthetic joint infections. *Orthopedics* 2012; **35**: e603-e606 [PMID: 22495870 DOI: 10.3928/01477447-20120327-42]

47 **Zborníková E**, Gallo J, Večeřová R, Bogdanová K, Kolář M, Vítovská D, Do Pham DD, Pačes O, Mojr V, Šanderová H, Ulrichová J, Galandáková A, Čadek D, Hrdlička Z, Krásný L, Rejman D. Evaluation of Second-Generation Lipophosphonoxins as Antimicrobial Additives in Bone Cement. *ACS Omega* 2020; **5**: 3165-3171 [PMID: 32118132 DOI: 10.1021/acsomega.9b03072]

48 **Suhardi VJ**, Bichara DA, Kwok S, Freiberg AA, Rubash H, Malchau H, Yun SH, Muratoglu OK, Oral E. A Fully Functional Drug-Eluting Joint Implant. *Nat Biomed Eng* 2017; **1** [PMID: 29354321 DOI: 10.1038/s41551-017-0080]

49 **Jenkins J,** Nobbs AH, Verkade P, Su B. Characterisation of bactericidal titanium surfaces using electron microscopy. Microscopy Analysis 2018; 32: 15-19

50 **Alt V**, Bechert T, Steinrücke P, Wagener M, Seidel P, Dingeldein E, Domann E, Schnettler R. An in vitro assessment of the antibacterial properties and cytotoxicity of nanoparticulate silver bone cement. *Biomaterials* 2004; **25**: 4383-4391 [PMID: 15046929 DOI: 10.1016/j.biomaterials.2003.10.078]

51 **Shi Z**, Neoh KG, Kang ET, Wang W. Antibacterial and mechanical properties of bone cement impregnated with chitosan nanoparticles. *Biomaterials* 2006; **27**: 2440-2449 [PMID: 16338001 DOI: 10.1016/j.biomaterials.2005.11.036]

52 **Deb S**, Doiron R, Disilvio L, Punyani S, Singh H. PMMA bone cement containing a quaternary amine comonomer with potential antibacterial properties. *J Biomed Mater Res B Appl Biomater* 2008; **85**: 130-139 [PMID: 17806110 DOI: 10.1002/jbm.b.30925]

53 **Moojen DJF,** Vogely HC, Fleer A, Verbout AJ, Castelein RM, Dhert WJ. No efficacy of silver bone cement in the prevention of methicillin- sensitive Staphylococcal infections in a rabbit contaminated implant bed model*. J Orthop Res* 2009; **27**:1002–1007 [PMID: **19165770** DOI: [10.1002/jor.20854](https://doi.org/10.1002/jor.20854)]

54 **Prokopovich P**, Leech R, Carmalt CJ, Parkin IP, Perni S. A novel bone cement impregnated with silver-tiopronin nanoparticles: its antimicrobial, cytotoxic, and mechanical properties. *Int J Nanomedicine* 2013; **8**: 2227-2237 [PMID: 23818779 DOI: 10.2147/IJN.S42822]

55 **Miola M**, Bruno M, Maina G, Fucale G, Lucchetta G, Vernè E. Antibiotic-free composite bone cements with antibacterial and bioactive properties. A preliminary study. *Mater Sci Eng C Mater Biol Appl* 2014; **43**: 65-75 [PMID: 25175189 DOI: 10.1016/j.msec.2014.06.026]

56 **Perni S**, Thenault V, Abdo P, Margulis K, Magdassi S, Prokopovich P. Antimicrobial activity of bone cements embedded with organic nanoparticles. *Int J Nanomedicine* 2015; **10**: 6317-6329 [PMID: 26487803 DOI: 10.2147/IJN.S86440]

57 **Prokopovich P**, Köbrick M, Brousseau E, Perni S. Potent antimicrobial activity of bone cement encapsulating silver nanoparticles capped with oleic acid. *J Biomed Mater Res B Appl Biomater* 2015; **103**: 273-281 [PMID: 24819471 DOI: 10.1002/jbm.b.33196]

58 **Slane J**, Vivanco J, Rose W, Ploeg HL, Squire M. Mechanical, material, and antimicrobial properties of acrylic bone cement impregnated with silver nanoparticles. *Mater Sci Eng C Mater Biol Appl* 2015; **48**: 188-196 [PMID: 25579913 DOI: 10.1016/j.msec.2014.11.068]

59 **Abid CK**, Jain S, Jackeray R, Chattopadhyay S, Singh H. Formulation and characterization of antimicrobial quaternary ammonium dendrimer in poly(methyl methcarylate) bone cement. *J Biomed Mater Res B Appl Biomater* 2017; **105**: 521-530 [PMID: 26584408 DOI: 10.1002/jbm.b.33553]

60 **Miola M,** Fucale G, Maina G, Verné E. Composites bone cements with different viscosities loaded with a bioactive and antibacterial glass. *J Mater Sci* 2017; **52**: 5133-5146 [DOI: 10.1007/s10853-017-0750-1]

61 **Russo T**, Gloria A, De Santis R, D'Amora U, Balato G, Vollaro A, Oliviero O, Improta G, Triassi M, Ambrosio L. Preliminary focus on the mechanical and antibacterial activity of a PMMA-based bone cement loaded with gold nanoparticles. *Bioact Mater* 2017; **2**: 156-161 [PMID: 29744425 DOI: 10.1016/j.bioactmat.2017.05.002]

62 **Miola M**, Cochis A, Kumar A, Arciola CR, Rimondini L, Verné E. Copper-Doped Bioactive Glass as Filler for PMMA-Based Bone Cements: Morphological, Mechanical, Reactivity, and Preliminary Antibacterial Characterization. *Materials (Basel)* 2018; **11** [PMID: 29882763 DOI: 10.3390/ma11060961]

63 **Verné E,** Foroni F, Lucchetta G, Miola M. Antibacterial and bioactive composite bone cements. *Curr Mater Sci* 2020; **12**: 144-153 [DOI: 10.2174/1874464812666190819143740]

64 **Valencia Zapata ME**, Mina Hernandez JH, Grande Tovar CD, Valencia Llano CH, Diaz Escobar JA, Vázquez-Lasa B, San Román J, Rojo L. Novel Bioactive and Antibacterial Acrylic Bone Cement Nanocomposites Modified with Graphene Oxide and Chitosan. *Int J Mol Sci* 2019; **20** [PMID: 31208091 DOI: 10.3390/ijms20122938]

65 **Zapata MEV**, Ruiz Rojas LM, Mina Hernández JH, Delgado-Ospina J, Tovar CDG. Acrylic Bone Cements Modified with Graphene Oxide: Mechanical, Physical, and Antibacterial Properties. *Polymers (Basel)* 2020; **12** [PMID: 32784747 DOI: 10.3390/polym12081773]

66 **Zapata MEV,** Hernandez JHM, Grande Tovar CD, Llano CHV, Vázquez-Lasa B, San Román J, Rojo L. Osseointegration of antimicrobial acrylic bone cements modified with graphene oxide and chitosan. *Appl Sci* 2020; **10**: 6528 [DOI: 10.3390/app10186528]

67 **Sukhonthamarn K**, Cho J, Chisari E, Goswami K, Arnold WV, Parvizi J. N-acetylcysteine use as an adjuvant to bone cement to fight periprosthetic joint infections: A preliminary in vitro efficacy and biocompatibility study. *J Orthop Res* 2021; **39**: 356-364 [PMID: 33179364 DOI: 10.1002/jor.24910]

68 **Wekwejt M**, Chen S, Kaczmarek-Szczepańska B, Nadolska M, Łukowicz K, Pałubicka A, Michno A, Osyczka AM, Michálek M, Zieliński A. Nanosilver-loaded PMMA bone cement doped with different bioactive glasses - evaluation of cytocompatibility, antibacterial activity, and mechanical properties. *Biomater Sci* 2021; **9**: 3112-3126 [PMID: 33704333 DOI: 10.1039/d1bm00079a]

69 **Bistolfi A**, Ferracini R, Albanese C, Vernè E, Miola M. PMMA-Based Bone Cements and the Problem of Joint Arthroplasty Infections: Status and New Perspectives. *Materials (Basel)* 2019; **12** [PMID: 31810305 DOI: 10.3390/ma12234002]

70 **Tan HL**, Ao HY, Ma R, Lin WT, Tang TT. In vivo effect of quaternized chitosan-loaded polymethylmethacrylate bone cement on methicillin-resistant Staphylococcus epidermidis infection of the tibial metaphysis in a rabbit model. *Antimicrob Agents Chemother* 2014; **58**: 6016-6023 [PMID: 25070107 DOI: 10.1128/AAC.03489-14]

71 **Wang M**, Sa Y, Li P, Guo Y, Du Y, Deng H, Jiang T, Wang Y. A versatile and injectable poly(methyl methacrylate) cement functionalized with quaternized chitosan-glycerophosphate/nanosized hydroxyapatite hydrogels. *Mater Sci Eng C Mater Biol Appl* 2018; **90**: 264-272 [PMID: 29853090 DOI: 10.1016/j.msec.2018.04.075]

72 **Wekwejt M**, Michno A, Truchan K, Pałubicka A, Świeczko-Żurek B, Osyczka AM, Zieliński A. Antibacterial Activity and Cytocompatibility of Bone Cement Enriched with Antibiotic, Nanosilver, and Nanocopper for Bone Regeneration. *Nanomaterials (Basel)* 2019; **9** [PMID: 31382557 DOI: 10.3390/nano9081114]

73 **Lin X**, Ge J, Wei D, Liu C, Tan L, Yang H, Yang K, Zhou H, Li B, Luo ZP, Yang L. Surface degradation-enabled osseointegrative, angiogenic and antiinfective properties of magnesium-modified acrylic bone cement. *J Orthop Translat* 2019; **17**: 121-132 [PMID: 31194022 DOI: 10.1016/j.jot.2019.04.007]

74 **Sathya S**, Murthy PS, Devi VG, Das A, Anandkumar B, Sathyaseelan VS, Doble M, Venugopalan VP. Antibacterial and cytotoxic assessment of poly (methyl methacrylate) based hybrid nanocomposites. *Mater Sci Eng C Mater Biol Appl* 2019; **100**: 886-896 [PMID: 30948126 DOI: 10.1016/j.msec.2019.03.053]

75 **Huh MW,** Kang I-K, Lee DH, Kim WS, Lee DH, Lee SP, Min KE, Seo KH. Surface characterization and antibacterial activity of chitosan-grafted poly(ethylene terephthalate) prepared by plasma glow discharge. *J Appl Polym Sci* 2001; **81**: 2769-2778 [DOI: 10.1002/app.1723]

76 **Marambio-Jones C,** Hoek EMV. A review of the antibacterial effects of silver nanomaterials and potential implications for human health and the environment. *J Nanoparticle Res* 2010; **12**: 1531-1551 [DOI: 10.1007/s11051-010-9900-y]

77 **Sadoon AA**, Khadka P, Freeland J, Gundampati RK, Manso RH, Ruiz M, Krishnamurthi VR, Thallapuranam SK, Chen J, Wang Y. Silver Ions Caused Faster Diffusive Dynamics of Histone-Like Nucleoid-Structuring Proteins in Live Bacteria. *Appl Environ Microbiol* 2020; **86** [PMID: 31953329 DOI: 10.1128/AEM.02479-19]

78 **Pollini M**, Paladini F, Catalano M, Taurino A, Licciulli A, Maffezzoli A, Sannino A. Antibacterial coatings on haemodialysis catheters by photochemical deposition of silver nanoparticles. *J Mater Sci Mater Med* 2011; **22**: 2005-2012 [PMID: 21691829 DOI: 10.1007/s10856-011-4380-x]

79 **Yoshida Y**, Furuta S, Niki E. Effects of metal chelating agents on the oxidation of lipids induced by copper and iron. *Biochim Biophys Acta* 1993; **1210**: 81-88 [PMID: 8257723 DOI: 10.1016/0005-2760(93)90052-b]

80 **Allan I**, Newman H, Wilson M. Antibacterial activity of particulate bioglass against supra- and subgingival bacteria. *Biomaterials* 2001; **22**: 1683-1687 [PMID: 11374470 DOI: 10.1016/s0142-9612(00)00330-6]

81 **Hu S**, Chang J, Liu M, Ning C. Study on antibacterial effect of 45S5 Bioglass. *J Mater Sci Mater Med* 2009; **20**: 281-286 [PMID: 18763024 DOI: 10.1007/s10856-008-3564-5]

82 **Samal S,** Das PK. Microbial biofilms: pathogenicity and treatment strategies. *Pharmatutor* 2018; **6**: 16-22 [DOI: 10.29161/pt.v6.i1.2018.16]

83 **Markowska K**, Grudniak AM, Wolska KI. Silver nanoparticles as an alternative strategy against bacterial biofilms. *Acta Biochim Pol* 2013; **60**: 523-530 [PMID: 24432308 DOI: 10.18388/abp.2013\_2016]

84 **Mangadlao JD**, De Leon AC, Felipe MJ, Cao P, Advincula PA, Advincula RC. Grafted carbazole-assisted electrodeposition of graphene oxide. *ACS Appl Mater Interfaces* 2015; **7**: 10266-10274 [PMID: 25928838 DOI: 10.1021/acsami.5b00857]

85 **Zheng K,** Taccardi N, Beltrán AM, Sui B, Zhou T, Reddy Marthala VR, Hartmann M, Boccaccini AR. Timing of calcium nitrate addition affects morphology, dispersity and composition of bioactive glass nanoparticles. *RSC Adv* 2016; **6**: 95101-95111 [DOI: 10.1039/c6ra05548f]

86 **Pahlevanzadeh F**, Bakhsheshi-Rad HR, Hamzah E. In-vitro biocompatibility, bioactivity, and mechanical strength of PMMA-PCL polymer containing fluorapatite and graphene oxide bone cements. *J Mech Behav Biomed Mater* 2018; **82**: 257-267 [PMID: 29627737 DOI: 10.1016/j.jmbbm.2018.03.016]

87 **Hamilton V,** Yuan Y, Rigney DA. Bone cell attachment and growth on well-characterized chitosan films. *Polym Int* 2007; **56**: 641-647 [DOI: 10.1002/pi.2181]

88 **Soares P**, Dias-Netipanyj MF, Elifio-Esposito S, Leszczak V, Popat K. Effects of calcium and phosphorus incorporation on the properties and bioactivity of TiO2 nanotubes. *J Biomater Appl* 2018; **33**: 410-421 [PMID: 30223734 DOI: 10.1177/0885328218797549]

89 **Rowson C**, Townsend R. Biofilms: prevention and treatment. *Br J Hosp Med (Lond)* 2016; **77**: 699-703 [PMID: 27937018 DOI: 10.12968/hmed.2016.77.12.699]

90 **Arciola CR**, Campoccia D, Montanaro L. Implant infections: adhesion, biofilm formation and immune evasion. *Nat Rev Microbiol* 2018; **16**: 397-409 [PMID: 29720707 DOI: 10.1038/s41579-018-0019-y]

91 **Scheper H**, Wubbolts JM, Verhagen JAM, de Visser AW, van der Wal RJP, Visser LG, de Boer MGJ, Nibbering PH. SAAP-148 Eradicates MRSA Persisters Within Mature Biofilm Models Simulating Prosthetic Joint Infection. *Front Microbiol* 2021; **12**: 625952 [PMID: 33584628 DOI: 10.3389/fmicb.2021.625952]

92 **Römling U**, Balsalobre C. Biofilm infections, their resilience to therapy and innovative treatment strategies. *J Intern Med* 2012; **272**: 541-561 [PMID: 23025745 DOI: 10.1111/joim.12004]

93 **Subramani R,** Jayaprakashvel M. Bacterial quorum sensing: biofilm formation, survival behaviour and antibiotic resistance. In: Bramhachari P. Implication of quorum sensing and biofilm formation in medicine, agriculture and food industry. Springer Singapore, 21-37 [DOI: 10.1007/978-981-32-9409-7\_3]

94 **Aguilera-Correa J-J,** Esteban J, Romero-Garcia D. Mechanics of biofilm formation in clinically used biomaterials, In: Mitra A. Microbial biofilms: current research and practical implications. Caister Academic Press, Norfolk, UK

95 **Ratner BD,** Hoffman AS, Schoen FJ, Lemons JE. Biomaterials science: an introduction to materials in medicine, 2nd edition. Elsevier Academic Press, San Diego, CA, USA

96 **Acharya S**, Panicker AG, Gopal V, Dabas SS, Manivasagam G, Suwas S, Chatterjee K. Surface mechanical attrition treatment of low modulus Ti-Nb-Ta-O alloy for orthopedic applications. *Mater Sci Eng C Mater Biol Appl* 2020; **110**: 110729 [PMID: 32204039 DOI: 10.1016/j.msec.2020.110729]

97 **Wu CT,** Chang HZ, Wu CY, Chen SW, Huang SY, Huang M, Pan YT, Bradbury P, Chou J, Yen HW. Machine learning recommends affordable new Ti alloy with bone-like modulus. *Mater Today* 2020; **34**: 41-50 [DOI: 10.1016/j.mattod.2019.08.008]

98 **Hoppe V**, Szymczyk-Ziółkowska P, Rusińska M, Dybała B, Poradowski D, Janeczek M. Assessment of Mechanical, Chemical, and Biological Properties of Ti-Nb-Zr Alloy for Medical Applications. *Materials (Basel)* 2020; **14** [PMID: 33396757 DOI: 10.3390/ma14010126]

99 **Huang Q**, Xu S, Ouyang Z, Yang Y, Liu Y. Multi-scale nacre-inspired lamella-structured Ti-Ta composites with high strength and low modulus for load-bearing orthopedic and dental applications. *Mater Sci Eng C Mater Biol Appl* 2021; **118**: 111458 [PMID: 33255043 DOI: 10.1016/j.msec.2020.111458]

100 **Hwang YJ**, Choi YS, Hwang YH, Cho HW, Lee DG. Biocompatibility and Biological Corrosion Resistance of Ti-39Nb-6Zr-0.45Al Implant Alloy. *J Funct Biomater* 2020; **12** [PMID: 33383616 DOI: 10.3390/jfb12010002]

101 **Hanada S,** Masahashi N, Semboshi S, Jung TK. Low Young’s modulus of cold groove-rolled β Ti-Nb-Sn alloys for orthopedic applications. *Mater Sci Eng A* 2021; **802**: 140645 [DOI: 10.1016/j.msea.2020.140645]

102 **Raina S**, De Vizio D, Odell M, Clements M, Vanhulle S, Keshavarz T. Microbial quorum sensing: a tool or a target for antimicrobial therapy? *Biotechnol Appl Biochem* 2009; **54**: 65-84 [PMID: 19594442 DOI: 10.1042/BA20090072]

103 **Kalia VC**, Wood TK, Kumar P. Evolution of resistance to quorum-sensing inhibitors. *Microb Ecol* 2014; **68**: 13-23 [PMID: 24194099 DOI: 10.1007/s00248-013-]

104 **Gajdács M**, Spengler G. The Role of Drug Repurposing in the Development of Novel Antimicrobial Drugs: Non-Antibiotic Pharmacological Agents as Quorum Sensing-Inhibitors. *Antibiotics (Basel)* 2019; **8** [PMID: 31861228 DOI: 10.3390/antibiotics8040270]

105 **Singh BP,** Ghosh S, Chauhan A. Development, dynamics and control of antimicrobial-resistant bacterial biofilms: a review. *Environ Chem Lett* 2021; **19**: 1983-1993 [DOI: 10.1007/s10311-020-01169-5]

106 **Bordi C**, de Bentzmann S. Hacking into bacterial biofilms: a new therapeutic challenge. *Ann Intensive Care* 2011; **1**: 19 [PMID: 21906350 DOI: 10.1186/2110-5820-1-19]

107 **Rogers GB**, Carroll MP, Bruce KD. Enhancing the utility of existing antibiotics by targeting bacterial behaviour? *Br J Pharmacol* 2012; **165**: 845-857 [PMID: 21864314 DOI: 10.1111/j.1476-5381.2011.01643.x]

108 **Whiteley M**, Diggle SP, Greenberg EP. Progress in and promise of bacterial quorum sensing research. *Nature* 2017; **551**: 313-320 [PMID: 29144467 DOI: 10.1038/nature24624]

109 **Carradori S**, Di Giacomo N, Lobefalo M, Luisi G, Campestre C, Sisto F. Biofilm and Quorum Sensing inhibitors: the road so far. *Expert Opin Ther Pat* 2020; **30**: 917-930 [PMID: 32985271 DOI: 10.1080/13543776.2020.1830059]

110 **Haque M**, Islam S, Sheikh MA, Dhingra S, Uwambaye P, Labricciosa FM, Iskandar K, Charan J, Abukabda AB, Jahan D. Quorum sensing: a new prospect for the management of antimicrobial-resistant infectious diseases. *Expert Rev Anti Infect Ther* 2021; **19**: 571-586 [PMID: 33131352 DOI: 10.1080/14787210.2021.1843427]

111 **ASTM**. F2118-14 (2020) Standard test method for constant amplitude of force controlled fatigue testing of acrylic bone cement materials. [cited 20 July 2021]. Available from: https://www.astm.org/Standards/F2118.htm

112 **ISO**. ISO 16402:2008 (2020) Implants for surgery-Acrylic resin cement-Flexural fatigue testing of acrylic resin cements used in orthopaedics. [cited 20 July 2021]. Available from: https://www.iso.org/standard/32212.html

113 **Bjarnsholt T**, Ciofu O, Molin S, Givskov M, Høiby N. Applying insights from biofilm biology to drug development - can a new approach be developed? *Nat Rev Drug Discov* 2013; **12**: 791-808 [PMID: 24080700 DOI: 10.1038/nrd4000]

114 **Sun T**, Hao H, Hao WT, Yi SM, Li XP, Li JR. Preparation and antibacterial properties of titanium-doped ZnO from different zinc salts. *Nanoscale Res Lett* 2014; **9**: 98 [PMID: 24572014 DOI: 10.1186/1556-276X-9-98]

115 **Lee JH**, Jo JK, Kim DA, Patel KD, Kim HW, Lee HH. Nano-graphene oxide incorporated into PMMA resin to prevent microbial adhesion. *Dent Mater* 2018; **34**: e63-e72 [PMID: 29402540 DOI: 10.1016/j.dental.2018.01.019]

116 **Karahaliloglu Z**, Kilicay E. In vitro evaluation of bone cements impregnated with selenium nanoparticles stabilized by phosphatidylcholine (PC) for application in bone. *J Biomater Appl* 2020; **35**: 385-404 [PMID: 32567484 DOI: 10.1177/0885328220933781]

117 **Wu J,** Zhu B, Zhao Y, Shi M, He X, Xu H, Zhou Q. One-step eco-friendly synthesis of Ag-reduced graphene oxide nanocomposites for antibiofilm application. *J Mater Eng Perform* 2020; **29**: 2551-2559 [DOI: 10.1007/s11665-020-04742-9]

118 **Bueloni B**, Sanna D, Garribba E, Castro GR, León IE, Islan GA. Design of nalidixic acid‑vanadium complex loaded into chitosan hybrid nanoparticles as smart strategy to inhibit bacterial growth and quorum sensing. *Int J Biol Macromol* 2020; **161**: 1568-1580 [PMID: 32777416 DOI: 10.1016/j.ijbiomac.2020.07.304]

119 **Zhang X,** Zhang Z, Shu Q. Copper clusters: an effective antibacterial for eradicating multidrug‐resistant bacterial infection in vitro and in vivo. *Adv Funct Mater* 2021; **31**: 2008720 [DOI: 10.1002/adfm.202008720]

120 **Mendili M**, Essghaier B, Seaward MRD, Khadhri A. In vitro evaluation of lysozyme activity and antimicrobial effect of extracts from four Tunisian lichens: Diploschistes ocellatus, Flavoparmelia caperata, Squamarina cartilaginea and Xanthoria parietina. *Arch Microbiol* 2021; **203**: 1461-1469 [PMID: 33388791 DOI: 10.1007/s00203-020-02129-x]

121 **Navarro-López DE**, Garcia-Varela R, Ceballos-Sanchez O, Sanchez-Martinez A, Sanchez-Ante G, Corona-Romero K, Buentello-Montoya DA, Elías-Zuñiga A, López-Mena ER. Effective antimicrobial activity of ZnO and Yb-doped ZnO nanoparticles against Staphylococcus aureus and Escherichia coli. *Mater Sci Eng C Mater Biol Appl* 2021; **123**: 112004 [PMID: 33812624 DOI: 10.1016/j.msec.2021.112004]

122 **Seyler TM**, Moore C, Kim H, Ramachandran S, Agris PF. A New Promising Anti-Infective Agent Inhibits Biofilm Growth by Targeting Simultaneously a Conserved RNA Function That Controls Multiple Genes. *Antibiotics (Basel)* 2021; **10** [PMID: 33406640 DOI: 10.3390/antibiotics10010041]

123 **Keri RS**, Patil MR, Patil SA, Budagumpi S. A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry. *Eur J Med Chem* 2015; **89**: 207-251 [PMID: 25462241 DOI: 10.1016/j.ejmech.2014.10.059]

124 **Morsy MA**, Ali EM, Kandeel M, Venugopala KN, Nair AB, Greish K, El-Daly M. Screening and Molecular Docking of Novel Benzothiazole Derivatives as Potential Antimicrobial Agents. *Antibiotics (Basel)* 2020; **9** [PMID: 32365587 DOI: 10.3390/antibiotics9050221]

125 **Singer L**, Bierbaum G, Kehl K, Bourauel C. Evaluation of the antimicrobial activity and compressive strength of a dental cement modified using plant extract mixture. *J Mater Sci Mater Med* 2020; **31**: 116 [PMID: 33247427 DOI: 10.1007/s10856-020-06455-w]

126 **Hasan M**, Altaf M, Zafar A, Hassan SG, Ali Z, Mustafa G, Munawar T, Saif MS, Tariq T, Iqbal F, Khan MW, Mahmood A, Mahmood N, Shu X. Bioinspired synthesis of zinc oxide nano-flowers: A surface enhanced antibacterial and harvesting efficiency. *Mater Sci Eng C Mater Biol Appl* 2021; **119**: 111280 [PMID: 33321572 DOI: 10.1016/j.msec.2020.111280]

**Footnotes**

**Conflict-of-interest statement:** The author declares that he has no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 7, 2021

**First decision:** October 17, 2021

**Article in press:**

**Specialty type:** Orthopedics

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Ghaffar KA, Egypt **S-Editor:** Wang LL **L-Editor:** A **P-Editor:** Wang LL

**Table 1 Key trendsa in a selection of properties of antibiotic-free antimicrobial poly (methyl methacrylate) bone cements**

|  |  |  |  |
| --- | --- | --- | --- |
| **Property** | **Loaded additiveb in AFAMBC formulation** | **Magnitude of trendc** | **Ref.** |
| Tensile modulus | 15%CS; 15% CS NP; 15% QCS NP; 10% QAMA; 5% TPGDA G1.0 | ↓; approximately; approximately; approximately; approximately | Shi *et al*[51]; Shi *et al*[51]; Shi *et al*[51]; Deb *et al*[52]; Abid *et al*[59] |
| Tensile strength | 10% QAMA; 5% TPGDA G1.0 | approximately; approximately | Deb *et al*[52]; Abid *et al*[59] |
| Compressive modulus | 0.5% Ag NP; 5% TPGDA G1.0; 0.25% Au NP | ↓; ↓; approximately | Slane *et al*[58]; Abid *et al*[59]; Russo *et al*[61] |
| Compressive strength | 10% QAMA; 1% Ag-TIOP NP; 30% SBAG; 7% PP NP; 0.05% Ag-OA NP; 0.5% Ag NP; 5% TPGDA G1.0; 0.25% Au NP; 10% Cu-SBA3 NP; 0.3% GO; 15% CS; 0.3% GO-15% CS | approximately; approximately; approximately; approximately; approximately; ↓; approximately; approximately; approximately; approximately; ↓; ↓ | Deb *et al*[52]; Prokopovich *et al*[54]; Miola *et al*[55]; Perni *et al*[56]; Prokopovich *et al*[57]; Slane *et al*[58]; Abid *et al*[59]; Russo *et al*[61]; Miola *et al*[62]; Zapata *et al*[64,66]; Zapata *et al*[64,66]; Zapata *et al*[64,66] |
| Flexural modulus | CS; CS NP; QCS NP; 0.5% Ag NP; 20% Ag-SBA2 NP; 10-50% NAC; 0.3% GO; 15% CS; 0.3% GO-15% CS | ↓; approximately; approximately; approximately; approximately; ↓; approximately; ↓; ↓ | Shi *et al*[51]; Shi *et al*[51]; Shi *et al*[51]; Slane *et al*[58]; Verne *et al*[63]; Sukhonthamarn *et al*[67]; Zapata *et al*[66]; Zapata *et al*[66]; Zapata *et al*[66] |
| Flexural strength | 0.5% Ag NP; 20% Ag-SBA2 NP; 10-50% NAC; 0.3% GO; 15% CS; 0.3% GO-15% CS | approximately; ↓; ↓; approximately; ↓; approximately | Slane *et al*[58]; Verne *et al*[63]; Sukhonthamarn *et al*[67]; Zapata *et al*[66]; Zapata *et al*[66]; Zapata *et al*[66] |
| Fracture toughness | 0.5% Ag NP | approximately | Slane *et al*[58] |
| Storage modulus and loss; modulus vs. time profile | 7% PP NP | approximately | Perni *et al*[56] |
| Elastic modulus vs. depth | 0.05% Ag-OA NP | approximately | Prokopovich *et al*[57] |
| Maximum polymerization | 10% QAMA; 0.3% GO; 15% CS; 0.3% GO-15% CS; BC-BG-MP-Ag NP | ↓; approximately; approximately; ↓; approximately | Deb *et al*[52]; Zapata *et al*[66]; Zapata *et al*[66]; Zapata *et al*[66]; Wekwejt *et al*[68] |
| Setting time | 10% QAMA; 0.3% GO; 15% CS; 0.3% GO-15% CS; BC-BG-MP-Ag NP | ↑; approximately; ↑; ↑; approximately | Deb *et al*[52]; Zapata *et al*[66]; Zapata *et al*[66]; Zapata *et al*[66]; Wekwejt *et al*[68] |
| Water contact angle | 5% TPGDA G1.0; 10% TPDGA G1.0; 0.1% GO; 0.2% GO; 0.3% GO; 0.5% GO; BC-BGII-0.4-Ag NP; BC-BG-MP-Ag NP | ↓; ↓; ↓; ↓; ↓; ↓; ↑; ↑ | Abid *et al*[59]; Abid *et al*[59]; Zapata *et al*[65]; Zapata *et al*[65]; Zapata *et al*[65]; Zapata *et al*[65]; Wekwejt *et al*[68]; Wekwejt *et al*[68] |
| Radiopacity | 10% QAMA; 20% Ag-SBA2 NP | approximately; ↑ | Deb *et al*[52]; Verné *et al*[63] |
| Residual monomer content | 15% CS; 0.3% GO-15% CS; 0.1% GO; 0.2% GO; 0.3% GO | ↑; ↑; approximately; approximately; ↑; ↑ | Zapata *et al*[64]; Zapata *et al*[64]; Zapata *et al*[65]; Zapata *et al*[65]; Zapata *et al*[65]; Zapata *et al*[65] |
| Uptake of PBS, at 37 oC, *vs* test time profile | 0.05% Ag-OA NP; 15% CS; 0.3% GO-15% CS | approximately; ↑; ↑ | Prokopovich *et al*[57]; Zapata *et al*[64]; Zapata *et al*[64] |

aTrend is ratio of mean value of property of antibiotic-free antimicrobial poly (methyl methacrylate) bone cement (AFAMBC) to that of a plain counterpart control cement (no antimicrobial additive), except in the study by Shi *et al*[51], in which the counterpart control cement was an approved antibiotic-loaded bone cement.

bCS: chitosan.

c:↓: Ratio is much less than 1 (mean property value for AFAMBC significantly lower than that for control cement); Approximately: Ratio is about 1 (difference in mean property values not significant); ↑: Ratio is much greater than 1 (mean property value for AFAMBC significantly higher than that for control cement). CS NP: Chitosan nanoparticles; QCS NP: Quaternary ammonium chitosan derivative nanoparticles; QAMA: Quaternary amine dimethacrylate; TPGDA G1.0: Generation-1 tripropylene glycol diacrylate dendrimer; Ag NP: Silver nanoparticles; Au NP: Gold nanoparticles; Ag-TIOP NP: Silver nanoparticles capped with tiopronin; SBAG: Particles of Na2O-CaO-P2O5-B2O3-Al2O3-Ag2O glass; PP NP: Propylparaben nanoparticles; Ag-OA NP: Silver nanoparticles capped with oleic acid; Cu-SBA3 NP: Powder of copper-doped bioactive glass (48% SiO2-26% Na2O-22% CaO-3% P2O5-0.43% B2O3-0.57% Al2O3) nanoparticles; GO: Graphene oxide nanosheets; Ag-SBA2 NP: Powder of silver-doped bioactive glass (SiO2-Na2O-CaO-P2O5- B2O3-Al2O3) (< 20 mm) nanoparticles; NAC: N-acetylcysteine; BC-BG-MP-Ag NP: A composite cement comprising bone cement, a Bioglass (70 mol%SiO2/30 mol%CaO), and silver nanoparticles; BC-BGII-Ag NP: A composite cement comprising a Bioglass and silver nanoparticles.